RDY — Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited (RDY) Q3 FY '26 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: INR 8,727 crores (USD 971 million), up 4.4% year-over-year, down 0.9% sequentially.
• EBITDA: INR 2,049 crores (USD 228 million), down 11% year-over-year and 13% sequentially; EBITDA margin at 23.5% (24.8% adjusted for a one-time provision related to new labor laws).
• Net Profit: INR 1,210 crores (USD 135 million), down 14% year-over-year and 16% sequentially; diluted EPS at INR 14.52.
• Gross Margin: 53.6%, down 505 basis points year-over-year; 57.4% for global generics.
• R&D Spend: INR 615 crores (USD 68 million), 7% of revenues, down 8% year-over-year.
• SG&A Spend: INR 2,692 crores (USD 300 million), 31% of revenue, up 12% year-over-year.
• Net Cash Surplus: INR 3,069 crores (USD 342 million).

2. Strategic Updates and Business Highlights

• Base Business Growth: Excluding Lenalidomide, the underlying base business saw double-digit growth, supported by strong performances in India and emerging markets.
• New Product Launches: Launched 10 new generics and progressed with the integration of the Nicotine Replacement Therapy (NRT) business, which is now 85% operationally integrated.
• Pipeline Progress: Received marketing authorization for semaglutide in India and completed the filing for abatacept biosimilar.
• Collaborations: Entered a strategic collaboration with Immutep for an oncology drug, with potential milestones of up to $350 million.
• Sustainability Initiatives: Committed to a net-zero climate target by FY2045.

3. Forward Guidance and Outlook

• India Business Growth: Expected to sustain a growth rate of 15% or higher, with the potential for semaglutide and NRT to contribute positively.
• EBITDA Margin: Anticipated to be in the range of 50% to 55% without Lenalidomide sales from Q4 FY '26 onwards.
• R&D Guidance: Expected to remain at 7% to 8% of revenues, with ongoing investments in new products.

4. Bad News, Challenges, or Points of Concern

• Declining Lenalidomide Sales: Significant impact on revenue and margins due to lower sales and pricing pressures in the U.S. and Europe.
• Margin Compression: Gross margins have declined due to adverse product mix and pricing pressures, with expectations of further compression post-Lenalidomide.
• Regulatory Challenges: Received a notice of noncompliance from Health Canada regarding semaglutide, which could delay approval.
• Competitive Pressures: Anticipated competition in the semaglutide market, particularly from Novo Nordisk, which may affect pricing dynamics.

5. Notable Q&A Insights

• India Growth Sustainability: Management indicated that the 19% growth in India is sustainable, with organic growth estimated between 17% and 18% when excluding acquisitions.
• Semaglutide Approval Timeline: Expected approval in Canada between February and May 2026, with a launch planned for March 2026 in India.
• Biosimilar Launches: Delays in denosumab and rituximab due to regulatory issues, with potential timelines extending into FY '27.
• SG&A Spend Outlook: While SG&A remains high, management expects moderation in growth rates as they prepare for the post-Lenalidomide era.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and challenges faced by Dr. Reddy's Laboratories, providing a balanced view of the company's current position and future outlook.